Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company's system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:DCTHD
Previous SymbolNASDAQ:DCTH
CUSIPN/A
Phone212-489-2100
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees46
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable
Delcath Systems (OTCMKTS:DCTHD) Frequently Asked Questions
What is Delcath Systems' stock symbol?
Delcath Systems trades on the OTCMKTS under the ticker symbol "DCTHD."
When did Delcath Systems' stock split? How did Delcath Systems' stock split work?
Delcath Systems's stock reverse split on the morning of Monday, November 6th 2017. The 1-350 reverse split was announced on Friday, November 3rd 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 3rd 2017. An investor that had 100 shares of Delcath Systems stock prior to the reverse split would have 0 shares after the split.
How were Delcath Systems' earnings last quarter?
Delcath Systems, Inc. (OTCMKTS:DCTHD) released its earnings results on Friday, November, 11th. The medical device company reported ($231.00) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1,151.50) by $920.50. The medical device company had revenue of $0.44 million for the quarter. During the same period in the prior year, the company posted ($686.00) earnings per share. View Delcath Systems' Earnings History.
Has Delcath Systems been receiving favorable news coverage?
Media headlines about DCTHD stock have trended somewhat positive on Thursday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Delcath Systems earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned media stories about the medical device company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future.
Who are some of Delcath Systems' key competitors?
Some companies that are related to Delcath Systems include 3M (MMM), Stryker (SYK), Becton Dickinson and (BDX), Boston Scientific (BSX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ResMed (RMD), ABIOMED (ABMD), Teleflex (TFX), DexCom (DXCM), Hill-Rom (HRC), Haemonetics (HAE), Insulet (PODD), ICU Medical (ICUI) and Globus Medical (GMED).
Who are Delcath Systems' key executives?
Delcath Systems' management team includes the folowing people:
- Roger G. Stoll Ph.D., Chairman of the Board (Age 74)
- Jennifer K. Simpson Ph.D., President, Chief Executive Officer, Director (Age 48)
- Barbra C. Keck, Chief Financial Officer, Secretary (Age 39)
- John Purpura, Executive Vice President - Global Head of Operations (Age 55)
- Simon C. Pedder Ph.D., Director (Age 56)
- William Dodge Rueckert, Independent Director (Age 64)
- Marco Taglietti M.D., Independent Director (Age 57)
How do I buy shares of Delcath Systems?
Shares of DCTHD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Delcath Systems' official website?
How can I contact Delcath Systems?
Delcath Systems' mailing address is 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019. The medical device company can be reached via phone at 212-489-2100 or via email at [email protected]
MarketBeat Community Rating for Delcath Systems (OTCMKTS DCTHD)
MarketBeat's community ratings are surveys of what our community members think about Delcath Systems and other stocks. Vote "Outperform" if you believe DCTHD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DCTHD will underperform the S&P 500 over the long term. You may vote once every thirty days.
